CAS 139110-80-8 Antiinfluenza Drug Zanamivir Pharmaceutical Raws Local Anesthetic Agents

Antiinfluenza Drug Zanamivir Pharmaceutical Raws CAS: 139110-80-8

Description:

Zanamivir is a medication used to treat and prevent influenza caused by influenza A and B viruses. It is a neuraminidase inhibitor and was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B.Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.

Basic Information:

Chemical name: Zanamivir
MF: C12H20N4O7
MW: 332.31
CAS: 139110-80-8
Appearance: white to off-white crystalline powder
Usage: Antiinfluenza agents

COA:

Medical uses:

Zanamivir is used for the treatment of infections caused by influenza A and influenza B viruses, but in otherwise-healthy individuals, benefits overall appear to be small. It decreases the risk of one's getting symptomatic, but not asymptomatic influenza. The combination of diagnostic uncertainty, the risk for virus strain resistance, possible side effects and financial cost outweigh the small benefits of zanamivir for the prophylaxis and treatment of healthy individuals.As of 2009, no influenza has shown any signs of resistance in the US.Since then, genes expressing resistance to zanamivir were found in Chinese people infected with avian influenza A H7N9 during treatment with zanamivir.

How should I use zanamivir?

Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

Treatment with zanamivir should start as soon as possible when flu symptoms appear, such as fever, chills, muscle aches, sore throat, and runny or stuffy nose.

Zanamivir is packaged in disk-shaped foil packs that contain 4 blisters of medicine. These disks are placed into a device called a DISKHALER that you will use to inhale the medicine. The device opens and loads a blister of zanamivir each time you use the inhaler. The disk device is not to be used with a spacer. Follow the patient instructions provided with the DISKHALER.

Dosage:

The recommended dose of zanamivir for the treatment of influenza in adults and paediatric patients aged 7 years and older is 10 mg bid (= twice daily 2 consecutive inhalations of one 5-mg blister) for 5 days.

On the first day of treatment, two doses should be taken at least 2 hours apart. On the following days, doses should be taken about 12 hours apart.

No dosage adjustment is required in patients with renal impairment (Cass 1999a).

Patients with pulmonary dysfunction should always have a fast-acting bronchodilator available and discontinue zanamivir if respiratory difficulty develops.

Our Advantage:

If you have any questions, please feel free to contact me:

If you have any question pls feel free to contact me via:

Email: export@senwayer.com
Whats-app:+86-18186442580
Wickr me:yukis8888
We-chat:+86-18186442580
Tele-gram:+86-18186442580